Expression and characterization of a mouse/human chimeric antibody specific for EGF receptor

Murine antibodies which recognize the epidermal growth factor receptor (EGF-r) are good candidates for therapy and diagnosis of tumours overexpressing this receptor. Here we report the isolation of the variable regions from a murine monoclonal antibody anti-EGF-r (Mint5), the procedure to obtain the...

Full description

Saved in:
Bibliographic Details
Published in:Journal of biotechnology Vol. 52; no. 1; pp. 51 - 60
Main Authors: Ferrer, Cristina, Anastasi, Anna M., Di Massimo, Anna M., Bullo, Angela, Di Loreto, Mario, Raucci, Giuseppe, Pacilli, Aurelio, Rotondaro, Luigi, Mauro, Sandro, Mele, Antonio, De Santis, Rita
Format: Journal Article
Language:English
Published: Lausanne Elsevier B.V 29-11-1996
Amsterdam Elsevier
New York, NY
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Murine antibodies which recognize the epidermal growth factor receptor (EGF-r) are good candidates for therapy and diagnosis of tumours overexpressing this receptor. Here we report the isolation of the variable regions from a murine monoclonal antibody anti-EGF-r (Mint5), the procedure to obtain the mouse/human chimeric antibody (chMint5) and its expression in COS, NS0 and CHO cells. The approach followed to construct chMint5 is based on the use of consensus primers specific for the ends of the variable regions. The sequence imposed by the primers did not affect the targeting potential of the antibody. In fact, the affinity of the chimeric antibody for EGF-r was nearly the same as that of the parental murine antibody. Based on previous in vitro and in vivo animal studies, Mint5 was shown to be a good candidate for the targeting of EGF-r overexpressing tumours. chMint5 is expected to be less immunogenic than murine antibody and therefore, could be useful for human treatment.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ObjectType-Article-1
ObjectType-Feature-2
ISSN:0168-1656
1873-4863
DOI:10.1016/S0168-1656(96)01625-2